Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Eur J Endocrinol ; 157(1): 63-8, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17609403

ABSTRACT

OBJECTIVE: An association between glycosylated hemoglobin (GHb) and cardiovascular mortality in nondiabetic individuals has recently been reported. Prompt detection of nondiabetic individuals with high-normal GHb and early cardiovascular involvement may be of value for preventive strategies. In this investigation, a possible relationship between GHb, aortic function and left ventricular (LV) mass in nondiabetic individuals has been studied. METHODS: A total of 263 nondiabetic African-Americans, aged 22-63 (mean 42 +/- 8) years were studied. All individuals were first degree relatives of diabetic patients, had normal oral glucose tolerance test (2-h OGTT) and decreased peripheral action of insulin. LV diameters and mass (echocardiography); ascending and abdominal aortic distensibility (echocardiography, arterial pressure); pulse wave velocity (PWV; electrocardiography, Doppler); fasting glucose; GHb; insulin sensitivity index (S(I)) and 2-h OGTT were measured. Multiple linear and logistic regression analyses were used to identify significant independent associations of fasting glucose; GHb; S(I) and 2-h OGTT with aortic function and LV mass. RESULTS: In fully adjusted multivariate logistic regression analysis, GHb predicted lower values of aortic distensibility (odds ratio (OR) 1.67 95% CI (1.04-2.75), P=0.04); higher PWV (OR 1.79 95% CI (1.09-2.93), P=0.022); and higher values of LV mass (OR 1.56 95% CI (1.08-2.88), P=0.029). Fasting glucose, S(I), and 2 h OGTT were not associated with aortic function and LV mass. CONCLUSION: Higher GHb concentrations, even within 'normal' range, are independently associated with stiffer aorta and increased LV mass and thus may detect nondiabetic individuals at increased cardiovascular risk.


Subject(s)
Aorta/physiology , Glycated Hemoglobin/metabolism , Heart Ventricles/anatomy & histology , Insulin Resistance , Adult , Blood Glucose/analysis , Cardiovascular Diseases/etiology , Echocardiography , Female , Glucose Tolerance Test , Heart Ventricles/diagnostic imaging , Humans , Linear Models , Male , Middle Aged , Organ Size , Risk Factors
2.
J Cardiopulm Rehabil ; 26(6): 355-60; quiz 361-2, 2006.
Article in English | MEDLINE | ID: mdl-17135854

ABSTRACT

PURPOSE: To determine the effectiveness of an intervention, directed toward the primary care physician (PCP), to improve the number of patients treated to low-density lipoprotein cholesterol (LDL-C) goal in a cardiac rehabilitation (CR) population. METHODS: A pre-post intervention cohort comparison using data collected from participants in a CR program with LDL-C > or =100 mg/dL at entry. The control cohort participated in CR between 1/00 and 10/02, 41.5% (n = 178) had an entry LDL-C > or =100 mg/dL. The intervention cohort participated in CR between 10/03 and 1/05, 26.4% (n = 67) had an entry LDL-C > or =100 mg/dL. The intervention group had identical treatment as the control group as well as the following: each participant with an LDL-C > or =100 mg/dL in the intervention cohort had an entry letter sent to his or her cardiologist and PCP from the programs Cardiology Medical Director, detailing the lipid goals and therapeutic options. In addition, monthly faxes on progress toward lipid goals were sent to the PCP. RESULTS: The control cohort was less likely to achieve LDL-C goal compared with the intervention cohort (43% vs 67%, respectively; P = .001). A patient was also less likely to have a lipid medication change during CR in the control group compared with the intervention group (29% vs 42%, respectively; P = .05). CONCLUSION: Use of systematic reminders directed at the PCP during CR can substantially increase the percentage of patients achieving nationally recognized LDL-C goals.


Subject(s)
Cholesterol, LDL/blood , Coronary Artery Disease/rehabilitation , Hyperlipidemias/drug therapy , Patient Care Team , Adrenergic beta-Antagonists/therapeutic use , Aged , Cholesterol/blood , Clopidogrel , Cohort Studies , Coronary Artery Disease/blood , Female , Humans , Hypolipidemic Agents/therapeutic use , Male , Patient Education as Topic , Platelet Aggregation Inhibitors/therapeutic use , Primary Health Care , Ticlopidine/analogs & derivatives , Ticlopidine/therapeutic use
3.
Ethn Dis ; 16(4): 830-6, 2006.
Article in English | MEDLINE | ID: mdl-17061734

ABSTRACT

OBJECTIVE: Metabolic syndrome (MetS) defines cardiovascular disease (CVD) risks. Despite higher rates of obesity, type 2 diabetes, and hypertension, African Americans have lower rates of MetS when compared to Caucasians, which is paradoxical, since African Americans are more insulin resistant and have higher rates of cardiovascular morbidity and mortality when compared to White Americans. We hypothesized that genetic inheritance predisposes African Americans to the greater cardiovascular risk and the associated morbidity and mortality. Therefore, we investigated the prevalence of components of MetS in obese, glucose-tolerant, first degree relatives of African American patients with type 2 diabetes. METHODS: We examined the clinical and metabolic characteristics of 201 first-degree relatives (159 females and 42 males, mean age 41 +/- 8 years, and mean body mass index (BMI) of 32 +/- 8 (kg/m2). The subjects were categorized with MetS according to the Adult Treatment Panel (ATP) III criteria. Insulin sensitivity (Bergman minimal model method) and insulin resistance (homeostasis model assessment [HOMA]) were determined. We compared the clinical and metabolic characteristics in the relatives with and without MetS. Where appropriate, we compared the prevalence of the components of MetS in our African American sample with those of African American data in the National Health and Nutrition Evaluation Survey (NHANES) III. RESULTS: Comparing the MetS group (n=65) vs control subjects (n=136), the mean age, BMI, and percent body fat were greater in the MetS group. Mean fasting serum glucose, insulin and C-peptide levels were also greater in the MetS group. Insulin resistance index (HOMA-IR) was higher in the MetS group (HOMA-IR: 3.7 +/- 2.7 vs 2.2 +/- 1.7, P=.0002). Mean insulin sensitivity tended to be lower in the MetS group (2.16 +/- 2.64 vs 2.82 +/- 2.31, P=.08). In addition, despite the moderately severe insulin resistance, the MetS group had very low serum triglyceride levels and was the parameter least likely to meet the ATP criteria. The metabolic cutoff points for ATP III criteria were much lower in African American first-degree relatives with MetS. Of the five components of the ATP III criteria, waist circumference was the single most common parameter to likely meet the MetS criteria. We found that the prevalence of MetS was 29% in women and 40% in men when compared with 20.9% in African American women and 13.9% for African American men in the NHANES III. CONCLUSION: We found that: 1) the prevalence of MetS is higher in a subgroup of African Americans who were first-degree relatives of patients with type 2 diabetes than that of African Americans in the NHANES III; and 2) waist circumference rather than metabolic parameters was the single most important parameter and was more likely to meet the MetS criteria in African American relatives.


Subject(s)
Black or African American/statistics & numerical data , Cholesterol, HDL/blood , Diabetes Mellitus, Type 2/ethnology , Insulin Resistance/ethnology , Metabolic Syndrome/ethnology , Obesity/ethnology , Triglycerides/blood , Adult , Biomarkers/blood , Blood Glucose/metabolism , Blood Pressure , Body Mass Index , C-Peptide/blood , Case-Control Studies , Cholesterol, LDL/blood , Diabetes Mellitus, Type 2/blood , Family , Female , Genetic Predisposition to Disease , Glucose Tolerance Test , Humans , Insulin/blood , Male , Metabolic Syndrome/blood , Middle Aged , Nutrition Surveys , Obesity/blood , Ohio/epidemiology , Pedigree , Prevalence , Research Design , Severity of Illness Index , Sex Factors , Waist-Hip Ratio
SELECTION OF CITATIONS
SEARCH DETAIL
...